Sunset Island Group, Inc.

OTCPK:SIGO Stock Report

Market Cap: US$34.4k

Sunset Island Group Valuation

Is SIGO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SIGO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SIGO ($0) is trading below our estimate of fair value ($0.06)

Significantly Below Fair Value: SIGO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SIGO?

Key metric: As SIGO is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for SIGO. This is calculated by dividing SIGO's market cap by their current book value.
What is SIGO's PB Ratio?
PB Ration/a
Book-US$2.43m
Market CapUS$34.39k

Price to Book Ratio vs Peers

How does SIGO's PB Ratio compare to its peers?

The above table shows the PB ratio for SIGO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.4x
HENC Hero Technologies
0.01xn/aUS$563.0
CBDL CBD Life Sciences
5xn/aUS$1.4m
VFRM Veritas Farms
0.4xn/aUS$81.9k
AMPE Ampio Pharmaceuticals
0.0009xn/aUS$3.0k
SIGO Sunset Island Group
n/an/aUS$34.4k

Price-To-Book vs Peers: Insufficient data to calculate SIGO's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Book Ratio vs Industry

How does SIGO's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

24 CompaniesPrice / BookEstimated GrowthMarket Cap
SIGO is unprofitableIndustry Avg. 1.8xNo. of Companies31PB01.22.43.64.86+
24 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: Insufficient data to calculate SIGO's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is SIGO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SIGO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ration/a
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SIGO's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

BeiGene

US$21.9b

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

BGNE

US$206.16

7D

8.2%

1Y

10.0%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

7D

2.5%

1Y

20.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

7D

-0.2%

1Y

-7.1%